Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: Comparison between methods based on planar scintigraphy

EJNMMI Research

Volumn 2, Issue 1, 2012, Pages 1-13

  Larsson, Maria ^a   Bernhardt, Peter ^a   Svensson, Johanna B ^a   Wängberg, Bo ^a   Ahlman, Håkan ^a   Forssell Aronsson, Eva ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Conjugate view method; Dosimetry; Kidney; Neuroendocrine tumor; Scintigraphy

Indexed keywords

ARGININE; LYSINE; OCTREOTATE LU 177; PENTETREOTIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DOSIMETRY; DRUG ABSORPTION; FEMALE; GAMMA CAMERA; HUMAN; INTERMETHOD COMPARISON; KIDNEY SIZE; KIDNEY TUBULE ABSORPTION; MALE; PLANAR SCINTIGRAPHY; PRIORITY JOURNAL; SCINTIGRAPHY;

EID: 84875340760     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-2-49     Document Type: Article

References (34)

1. Pool SE, Krenning EP, Koning GA, van Eijck CH, Teunissen JJ, Kam B, Valkema R, Kwekkeboom DJ, de Jong M: Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin Nucl Med 2010, 40:209-218.
2. Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW, Krenning EP: Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010, 17:R53-R73.
3. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, Schmidt MA, Bugaj JL, de Jong M, Krenning EP: [177Lu-DOTAOTyr3] octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med 2001, 28:1319-1325.
4. Sward C, Bernhardt P, Ahlman H, Wangberg B, Forssell-Aronsson E, Larsson M, Svensson J, Rossi-Norrlund R, Kolby L: [177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney. World Journal of Surgery 2010, 34:1368-1372.
5. Melis M, Krenning EP, Bernard BF, Barone R, Visser TJ, de Jong M: Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. Eur J Nucl Med Mol Imaging 2005, 32:1136-1143.
6. Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP: Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 2007, 21:111-129.
7. Rolleman EJ, Kooij PP, de Herder WW, Valkema R, Krenning EP, de Jong M: Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney. Eur J Nucl Med Mol Imaging 2007, 34:1854-1860.
8. Moncayo R: Cubilin and megalin in radiation-induced renal injury with labelled somatostatin analogues: are we just dealing with the kidney? Eur J Nucl Med Mol Imaging 2005, 32:1131-1135.
9. Rolleman EJ, Krenning EP, Van Gameren A, Bernard BF, De Jong M: Uptake of [111In-DTPA0]octreotide in the rat kidney is inhibited by colchicine and not by fructose. J Nucl Med 2004, 45:709-713.
10. Vegt E, de Jong M, Wetzels JF, Masereeuw R, Melis M, Oyen WJ, Gotthardt M, Boerman OC: Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med 2010, 51:1049-1058.
11. Verroust PJ, Christensen EI: Megalin and cubilin-the story of two multipurpose receptors unfolds. Nephrol Dial Transplant 2002, 17:1867-1871.
12. Vegt E, Melis M, Eek A, de Visser M, Brom M, Oyen WJ, Gotthardt M, de Jong M, Boerman OC: Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalindeficient mice. Eur J Nucl Med Mol Imaging 2011, 38:623-632.
13. Rolleman EJ, Melis M, Valkema R, Boerman OC, Krenning EP, de Jong M: Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging 2010, 37:1018-1031.
14. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, Kvols LK, Krenning EP, Jamar F, Pauwels S: Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005, 46(Suppl 1):99S-106S.
15. Cremonesi M, Ferrari ME, Bodei L, Bartolomei M, Chinol M, Mei R, Daou B, Tosi G, Paganelli G: Dosimetry in patients undergoing Lu-177-DOTATATE therapy with indications for Y-90-DOTATATE. Eur J Nucl Med Mol I 2006, 33:S102-S102.
16. Fleming JS: A technique for the absolute measurement of activity using a gamma camera and computer. Phys Med Biol 1979, 24:176-180.
17. Wehrmann C, Senftleben S, Zachert C, Muller D, Baum RP: Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm 2007, 22:406-416.
18. Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, Barone R, Walrand S, Kooij PP, Bakker WH, Lasher J, Krenning EP: Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 2005, 46(Suppl 1):83S-91S.
19. Sandstrom M, Garske U, Granberg D, Sundin A, Lundqvist H: Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging 2010, 37:212-225.
20. Garkavij M, Nickel M, Sjogreen-Gleisner K, Ljungberg M, Ohlsson T, Wingardh K, Strand SE, Tennvall J: 177Lu-[DOTA0, Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer 2010, 116:1084-1092.
21. Norrgren K, Svegborn SL, Areberg J, Mattsson S: Accuracy of the quantification of organ activity from planar gamma camera images. Cancer Biother Radiopharm 2003, 18:125-131.
22. Buijs WC, Siegel JA, Boerman OC, Corstens FH: Absolute organ activity estimated by five different methods of background correction. J Nucl Med 1998, 39:2167-2172.
23. ICRP89: Basic anatomical and physiological data for use in radiological protection: reference values. ICRP Publication 89 Ann ICRP 2002, 32:1-277.
24. ICRP38: Radionuclide transformations-energy and intensity of emissions. ICRP Publication 38 Ann ICRP 1983, 11-13:738-761.
25. ICRP107: Nuclear decay data for dosimetric calculations. ICRP Publication 2008, 38:1-96.
26. Nuclear Decay Data in the MIRD Format Database. http://nucleus.iaea.org/ sso/NUCLEUS.html?exturl=http://www-nds.iaea.org/mird/. Accessed March 14, 2012.
27. Enger SA, Hartman T, Carlsson J, Lundqvist H: Cross-fire doses from betaemitting radionuclides in targeted radiotherapy. A theoretical study based on experimentally measured tumor characteristics. Phys Med Biol 2008, 53:1909-1920.
28. Amato E, Lizio D, Baldari S: Absorbed fractions for electrons in ellipsoidal volumes. Phys Med Biol 2011, 56:357-365.
29. Amato E, Lizio D, Baldari S: Absorbed fractions for photons in ellipsoidal volumes. Phys Med Biol 2009, 54:N479-N487.
30. Snyder WS, Ford MR, Warner GG: MIRD pamphlet no. 5, revised: Estimates of specific absorbed fractions for photon sources uniformly distributed in various organs of a heterogeneous phantom. New York: Society of Nuclear Medicine; 1978.
31. Stabin MG, Siegel JA: Physical models and dose factors for use in internal dose assessment. Health physics 2003, 85:294-310.
32. Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, Baio SM, Sansovini M, Paganelli G: Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008, 35:1847-1856.
33. Forssell-Aronsson E, Lanhede B, Fjälling M, Wängberg B, Tisell LE, Ahlman H, Mattsson S: Pharmacokinetics and dosimetry of 111In-DTPA-D-Phe1-octreotide in patients with neuroendocrine tumors. In Sixth International Radiopharmaceutical Dosimetry Symposium: May 7-10, 1996; Gatlinburg, Tennessee. volume 2. Edited by Schlafke-Stelson A, Watson EE. Tennessee: ORISE 99-0164; 1999:643-654.
34. Jonsson L, Ljungberg M, Strand SE: Evaluation of accuracy in activity calculations for the conjugate view method from Monte Carlo simulated scintillation camera images using experimental data in an anthropomorphic phantom. J Nucl Med 2005, 46:1679-1686.